Ligand Binding to Macrophage Scavenger Receptor-A Induces Urokinase-type Plasminogen Activator Expression by a Protein Kinase-dependent Signaling Pathway*

Hsien-Yeh HsuDagger **, David P. Hajjar§, K. M. Faisal Khan§, and Domenick J. Falcone§par

From the Departments of Dagger  Medicine, § Pathology, and  Cell Biology and Anatomy, Cornell University Medical College, New York, New York 10021

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Macrophage scavenger receptor-type A (MSR-A) has been implicated in the transmission of cell signals and the regulation of diverse cellular functions (Falcone, D. J., and Ferenc, M. J. (1988) J. Cell. Physiol. 135, 387-396; Falcone, D. J., McCaffrey, T. A., and Vergilio, J. A. (1991) J. Biol. Chem. 266, 22726-22732; Palkama, T. (1991) Immunology 74, 432-438; Krieger, M., and Herz, J. (1994) Annu. Rev. Biochem. 63, 601-637); however, the signaling mechanisms are unknown. In studies reported here, we demonstrate that binding of both lipoprotein and non-lipoprotein ligands to MSR-A induced protein tyrosine phosphorylation and increased protein kinase C (PKC) activity leading to up-regulated urokinase-type plasminogen activator (uPA) expression. Specifically, the binding of acetylated low density lipoprotein and fucoidan to MSR-A in human THP-1 macrophages triggered tyrosine phosphorylation of many proteins including phospholipase C-gamma 1 and phosphatidylinositol-3-OH kinase. Inhibitors of tyrosine kinase dramatically reduced MSR-induced protein tyrosine phosphorylation and PKC activity. Moreover, inhibitors of tyrosine kinase and PKC reduced uPA activity expressed by THP-1 macrophages exposed to MSR-A ligands. The intracellular signaling response for tyrosine phosphorylation following ligand binding was further demonstrated by using the stable MSR-transfected Bowes cells that express surface MSR-A. These findings establish for the first time a signaling pathway induced by ligand binding to MSR-A and suggest a molecular model for the regulation of macrophage uPA expression by specific ligands of the MSR-A.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Atherosclerosis is a chronic inflammatory disease characterized by the early and persistent presence of macrophages (5-8). Following their migration from the blood and transformation into lipid-laden cells (foam cells), monocyte-derived macrophages play a multifaceted role in lesion development (5, 9). The mechanisms by which macrophages are transformed into foam cells are not fully characterized. It has been demonstrated that macrophages express scavenger receptors types A and B (MSR-A, -B)1 that mediate the high affinity binding and internalization of modified forms of low density lipoprotein (LDL) (4, 10). These forms include acetoacetylated LDL (11), acetylated LDL (Ac-LDL) (10), malondialdehyde-modified LDL (12, 13), and oxidized LDL (14-17). The expression of MSR-A in macrophages and foam cells in atherosclerotic lesions (18), supports the proposed role for scavenger receptors in atherosclerosis (4, 19-21).

In addition to modified lipoproteins, a diverse group of polyanionic ligands are recognized by the MSR (4). These include sulfated polysaccharides (fucoidan and dextran sulfate) (1, 2), polyribonucleotides (poly(I) and poly(G)) (1, 2, 22), lipopolysaccharide, and lipoteicholic acids from Gram-negative and positive bacteria, respectively (23), anionic phospholipids such as phosphatidylserine (24), crocidolite asbestos (25) and advanced glycation end products (26, 27). Owing to the broad nature of its ligand specificity, scavenger receptors have been proposed to play an important role in several macrophage functions including adhesion (27, 28), clearance of pathologic substances (23, 25), and host defenses (3, 4, 21).

Several recent studies have demonstrated alterations in macrophage function following incubation with MSR-A ligands (2-4). For example, various MSR-A ligands including Ac-LDL, fucoidan, poly(I), and dextran sulfate have been shown to up-regulate the expression of urokinase-type plasminogen activator (uPA) by murine RAW264.7 macrophages (2). The induction of uPA expression by fucoidan was protein kinase C-dependent and required protein and RNA synthesis (2). Importantly, the enhanced expression of uPA by RAW264.7 macrophages following Ac-LDL challenge leads to plasmin-dependent extracellular matrix degradation and the release of matrix-bound growth factors, such as basic fibroblast growth factor and transforming growth factor-beta (29). Taken together, these data suggest that the binding of specific ligands to the MSR-A may transmit a signaling response in the cell. However, direct evidence for MSR-mediated signal transduction event has not been demonstrated.

In studies reported here, we demonstrate for the first time MSR ligands can trigger signal transduction pathways involving protein kinases in the macrophage. In addition, we demonstrate that macrophage uPA secretion following incubation with lipoprotein and non-lipoprotein ligands of the MSR-A is indeed dependent on MSR-mediated signaling. Finally, using transfection approaches, we confirm that the observed signal transduction is dependent on expression of the MSR-A.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Disposable tissue culture materials were purchased from Corning Glass Works (Corning, NY). Medium RPMI 1640, macrophage serum-free medium, L-glutamine, penicillin, streptomycin, and fetal calf serum were purchased from Life Technologies, Inc. Leupeptin and aprotinin were obtained from Boehringer Mannheim (Germany). Calphostin C and herbimycin A were purchased from Calbiochem (La Jolla, CA). Wortmannin was purchased from Biomol Research Laboratories, Inc. (Plymouth Meeting, PA). Sodium orthovanadate was obtained from Aldrich. HEPES, NaCl, glycerol, Triton X-100, MgCl2, phenylmethylsulfonyl fluoride, phorbol 12-myristate 13-acetate (PMA), and bovine serum albumin (fraction V) were purchased from Sigma. Immobilon® membrane was purchased from Millipore. DuPont Western blot Chemiluminescence Reagent, Renaissance®, a non-radioactive light-emitting system was purchased from NEN Life Science Products. Plasmin substrate D-Val-Leu-Lys-aminomethylcoumarin was obtained from Enzyme Systems Products (Dublin, CA). Bovine plasminogen and high molecular weight uPA were obtained from American Diagnostica (Greenwich, CT). The Pfu DNA polymerase and pCR-scriptTM SK(+) cloning kit were obtained from Stratagene (La Jolla, CA). The vector pcDNA3, a selectable mammalian expression vector with a neomycin resistance marker, and calcium phosphate transfection kit for introduction of DNA into mammalian cells were obtained from Invitrogen (San Diego, CA). Human recombinant macrophage colony stimulating factor were obtained from R&D Systems, Minneapolis, MN. Anti-phosphotyrosine monoclonal antibody 4G10, anti-PLC-gamma 1 monoclonal antibody, and anti-PI 3-kinase polyclonal antibody were purchased from Upstate Biotechnology, Inc. Goat anti-mouse IgG- or anti-rabbit IgG-horseradish peroxidase conjugate was obtained from Boehringer Mannheim. Protein A/G plus-agarose was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Rabbit polyclonal anti-human uPA IgG was obtained from American Diagnostica. Rabbit polyclonal anti-human macrophage scavenger receptor antibody (hSRI-2 anti-macrophage scavenger receptor-A peptide antibody) was a gift from Dr. T. Kodama, University of Tokyo, Japan (18). Rabbit IgG, purified immunoglobulin from serum, was purchased from Sigma. Secondary antibody, goat F(ab')2 anti-rabbit immunoglobulin (gamma and light chains) fluorescein conjugates for Flow Cytometric analysis, was purchased from BioSource International (Camarillo, CA).

Cell Culture-- Human monocyte-like THP-1 cells were cultured as described previously (30). In this paper, suspension cultures of human monocytic THP-1 cells are referred to as THP-1 monocytes; PMA-differentiated macrophage-like THP-1 cells are referred to as PMA-differentiated THP-1 macrophage or THP-1 macrophage as described (30). Bowes human melanoma cells, obtained from Dr. D. B. Rifkin, New York University Medical Center, New York, were grown in Dulbecco's modified Eagle's medium with high glucose (Life Technologies, Inc.) plus 10% fetal calf serum. Transfected Bowes cells were grown in the same medium containing the neomycin analog Geneticin, G418 sulfate (Life Technologies, Inc.) at 500 µg/ml.

Determination of Plasminogen Activator Activity-- Plasminogen activator activity was quantitated utilizing a previously described modification of a sensitive functional assay for plasmin (29). Aliquots of serum-free conditioned media were added to microtiter wells containing 0.05% Dulbecco's phosphate-buffered saline containing Tween 20, plasmin substrate D-Val-Leu-Lys-aminomethylcoumarin, and bovine plasminogen. Samples were mixed and incubated at 37 °C for 2.5 h. Cleavage of the substrate was monitored by measuring the increase in fluorescence in a Fluoroscan microplate reader. Concentrations of uPA in the conditioned media were extrapolated from a standard curve utilizing high molecular weight uPA. Plasminogen activator activity in media was completely inhibited when preincubated with a polyclonal anti-human uPA IgG, as described previously (2).

Immunoprecipitation-- The methods for immunoprecipitation are described previously with some modification (30). Briefly, THP-1 macrophages or Bowes cells were grown in medium containing 0.01% fetal calf serum and maintained for 24 h prior to challenge with various reagents as indicated. Cell lysates were prepared in Triton lysis buffer (TL buffer: 20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 2 mM EDTA, pH 7.5, 1% Triton X-100, 25 mM beta -glycerophosphate, 1 mM sodium vanadate, 2 mM sodium pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin). Lysates were normalized for protein concentration and incubated with anti-PLC-gamma 1 monoclonal antibody or anti-PI 3-kinase polyclonal antibody at 4 °C for 24 h. The next day, protein A/G plus agarose was added to the immune complexes and incubated at 4 °C for 2 h. Precipitated immunoprecipitates were washed three times in fresh TL buffer. The pellets were solubilized in SDS sample buffer with mild reducing conditions (boiling for 10 min in the presence of 2-mercaptoethanol). Protein was loaded in each lane, separated by SDS-PAGE gel electrophoresis, and transferred to Immobilon® membrane.

Immunoblotting-- The methods for immunoblotting are described previously (30). Briefly, lysates were separated by SDS-PAGE and transferred to Immobilon® membranes. The membranes were blocked with blocking buffer (PBS + 0.1% Tween 20 with 1% BSA) at room temperature for 1 h with slowly shaking. Then the membranes were immunoblotted with anti-phosphotyrosine monoclonal antibody 4G10 in a new blocking buffer for 2 h at room temperature with slowly shaking. After blotting, the membranes were washed in washing buffer (PBS + 0.1% Tween 20, without 1% BSA) once for 15 min followed by two washes for 5 min. The membranes were blocked again in a new blocking buffer for 1 h at room temperature with slowly shaking and immunoblotted with appropriated secondary antibodies conjugated with horseradish peroxidase in the same blocking buffer for 1 h at room temperature with slowly shaking. Afterward, membranes were further washed in washing buffer once for 15 min followed by two washes for 5 min. Protein visualization on each immunoblot was developed and performed with Renaissance®, DuPont Western blot chemiluminescence reagent (NEN Life Science Products) as described previously (30).

Assay of Protein Kinase C Activity in THP-1 Macrophages-- THP-1 macrophages were treated with several agonists as described in Fig. 4. At the indicated time, cells were washed twice with 5 ml of ice-cold PBS (without Ca2+, Mg2+), harvested, and pelleted at 325 × g, 4 °C. The cell pellet was resuspended in TE (20 mM Tris, pH 7.4, 20 mM EDTA), containing 2 mM EGTA, 10 µg/ml leupeptin, 0.3 mM phenylmethylsulfonyl fluoride, and 10% glycerol. The assay for total PKC activity was performed as described previously (31) or with the use of the Amersham Protein Kinase C enzyme assay system (Amersham Corp.).

Assay of Protein Kinase A Activity from THP-1 Macrophages-- The cell pellet prepared was similar to the above PKC assay. To assay the PKA activity in the cell, we followed methods described previously (31) or used the Life Technologies, Inc., protein kinase A enzyme assay system (Life Technologies, Inc.).

Isolation of LDL and Preparation of Modified LDL-- Human LDL (d 1.019-1.063 g/ml) was prepared as described (32). LDL preparations were occasionally screened for peroxides (33).

RNA Isolation and Northern Analysis-- Total RNA was isolated by the guanidinium isothiocyanate method (34). Northern blot analyses were performed as described (31, 35). The cDNA for the human uPA (36) was purchased from ATCC (Rockville, MD). The cDNA for human 28 S ribosomal RNA was a gift from Dr. Iris L. Gonzalez, Hahnemann University, PA. RNA from Northern blots was quantified using a PhosphorImager® (Molecular Dynamics, CA) and normalized by comparison to mRNA of 28 S ribosomal RNA, a constitutively expressed gene.

Construction of N-MSR Expression Vectors, MSR cDNA Stable Transfection, and Transfectant Cell Culture-- The expression vectors pcDNA3-NMSR representing human normal macrophage scavenger receptor cDNA (N-MSR) was derived from the human MSR type A-I cDNA (37). The orientation and sequence of this construct were verified and confirmed by both restriction enzyme-digestion mapping and DNA sequencing using Perkin-Elmer/Applied Biosystems model 373 DNA Stretch Sequencer. Bowes cells were sub-passaged the day before transfection by using calcium phosphate transfection method as described (31), or the protocol provided in calcium phosphate transfection kit (Invitrogen). The pcDNA3-NMSR expression vector was transfected into 60% confluent Bowes. The next day, fresh medium was added, and selection began 24 h later with the addition of Geneticin, G418 sulfate (potency 500 µg/ml) to the medium. Transfected cells were then maintained continuously in Geneticin-containing media. On days 14-16, the surviving 60 colonies were picked and subsequently grown into mass transfectant cultures and for other experiments.

Flow Cytometric Analysis of Macrophage Scavenger Receptor-A Expression in MSR-transfected Bowes Cells-- Rabbit polyclonal anti-human MSR-A antibody (hSRI-2 anti-macrophage scavenger receptor peptide antibody) was used in the flow cytometric analysis. Bowes cells (wild type or transfected) were removed from culture dishes with a rubber policeman, washed three times with phosphate-buffered saline (PBS), and resuspended in PBS containing 1.0% bovine serum albumin. Cells were then aliquoted into 50-µl volumes containing 106 cells and incubated with the hSRI-2 antibody (150 µg/ml) or control rabbit IgG, purified immunoglobulin from serum, for 30 min rotated at 4 °C. The cells were then pelleted by centrifugation and washed two times with PBS, 1.0% BSA. Cells were then resuspended in PBS, 1.0% BSA with a 1:50 dilution of fluorescein-conjugated goat F(ab')2 anti-rabbit immunoglobulins and rotated for 30 min and at 4 °C. The cells were then pelleted, resuspended in 500 µl of PBS, and immediately analyzed with a Coulter Epics XL flow cytometer (Coulter Inc.)

Protein Assay-- Protein amounts were determined by the method of Lowry et al. (38) or the Bio-Rad protein assay.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Ac-LDL and Fucoidan Up-regulate THP-1 Macrophage uPA Expression-- The effect of lipoprotein and nonlipoprotein ligands of the MSR-A on uPA expression by macrophages was determined. For these studies, we utilized phorbol myristate acetate (PMA)-treated human THP-1 monocytes. Following PMA-induced differentiation of THP-1 monocytes into macrophage-like cells, MSR-A expression was up-regulated, and the cells became adherent (30, 39). Following a 12-h incubation with Ac-LDL or fucoidan, the steady state levels of uPA mRNA in THP-1 macrophages were dramatically increased compared with control cells or cells incubated with LDL. When examined at 24 h, Ac-LDL and fucoidan-induced increase in uPA mRNA levels remained elevated relative to control. In contrast, neither Ac-LDL nor fucoidan altered uPA mRNA levels in THP-1 monocytes, which are devoid of MSR-A activity (30) (data not shown).

We next determined whether the observed increase in uPA mRNA levels (Fig. 1) was reflected by an increase in the expression of uPA activity by THP-1 macrophages. Cells were incubated overnight in media alone or media supplemented with LDL, Ac-LDL, or fucoidan. As seen in Table I, there was a small increase (2-fold) in uPA activity expressed by THP-1 macrophages incubated with LDL. In contrast, incubation with the MSR-A ligands Ac-LDL and fucoidan stimulated uPA activity 5- and 10-fold, respectively. Taken together, these data corroborate and extend our earlier observations utilizing murine RAW264.7 macrophages (2).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 1.   Ligands of MSR-A increase steady state levels of uPA mRNA in human THP-1 macrophages. Total RNA was isolated from PMA-differentiated THP-1 macrophages grown in serum-free media. Northern blots were hybridized with 32P-labeled cDNAs of uPA or 28 S. The amounts of uPA RNA were quantitated using a PhosphorImager (Molecular Dynamics) and normalized by comparison to mRNA of 28 S, a constitutively expressed gene. Similar results were obtained in three separate experiments.

                              
View this table:
[in this window]
[in a new window]
 
Table I
MSR-A ligands stimulate THP-1 macrophage uPA expression
PMA-differentiated THP-1 macrophages were incubated with 100 µg/ml LDL, Ac/LDL, or fucoidan overnight in macrophage serum-free medium. The next day media were recovered and assayed for uPA activity as described under "Experimental Procedures." Data represents the mean ± S.E. of three separate samples. mU, milliunits.

Ac-LDL and Fucoidan Induce Protein Tyrosine Kinase and Protein Kinase C-- To determine whether MSR-A ligands trigger specific signal transduction pathways in THP-1 macrophages, tyrosine phosphorylation was determined following incubation with Ac-LDL and fucoidan. Cellular proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and probed with monoclonal anti-phosphotyrosine IgG. As seen in Fig. 2A, incubation of THP-1 macrophages with Ac-LDL and fucoidan induced the appearance of many phosphotyrosyl proteins when compared with cells incubated with media alone or native LDL. MSR-A ligands did not alter the expression of phosphotyrosyl proteins in THP-1 monocytes (data not shown).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Stimulation of protein tyrosine phosphorylation in THP-1 macrophages upon ligand binding to MSR-A. A, THP-1 macrophages were preincubated 24 h in 0.01% fetal calf serum. Cells were untreated (lane 1) or treated with 100 µg/ml LDL (lane 2), 100 µg/ml acetylated LDL (lane 3), 20 µg/ml fucoidan (lane 4) for 15 min at 37 °C. Cells were lysed in TL buffer and centrifuged. The supernatants were collected, and SDS sample buffer was added. The same amounts of protein were loaded onto each lane. Immunoreactive phosphorylated tyrosine proteins were identified by Western blot procedures as described under "Experimental Procedures." B, in a similar experiment, cells were preincubated (30 min) with or without herbimycin A (5 µM) and treated with 100 µg/ml acetyl-LDL (Ac-LDL, lanes 3 and 1, respectively) or with 20 µg/ml fucoidan (lanes 4 and 2, respectively). Immunoreactive phosphorylated tyrosine proteins were identified as described under "Experimental Procedures."

To investigate further the induction of phosphotyrosyl proteins by ligand binding to the MSR-A, we used the specific protein tyrosine kinase inhibitor, herbimycin A. As shown in Fig. 2B, preincubation of THP-1 macrophages with herbimycin A blocked the protein tyrosine phosphorylation observed in control cells following the addition of Ac-LDL or fucoidan.

Cell lysates derived from THP-1 macrophages incubated with MSR-A ligands contained 150-kDa (pp150) and 85-kDa (pp85) proteins that were prominently identified with anti-phosphotyrosine IgG (Fig. 2A). To explore further the identities of these two phosphotyrosyl proteins, cell lysates were incubated with monoclonal anti-phospholipase C-gamma 1 (PLC-gamma 1) IgG or polyclonal anti-phosphoinositol-3-OH kinase (PI 3-kinase) IgG. Immune complexes were recovered via incubation with protein A/G plus agarose. Immunoprecipitates were separated by SDS-PAGE and immunoblotted with monoclonal anti-phosphotyrosine IgG. As seen in Fig. 3, the 150-kDa phosphotyrosyl protein was immunoreactive with anti-PLC-gamma 1 IgG and the 85-kDa phosphotyrosyl protein was immunoreactive with anti-PI 3-kinase IgG. Taken together, these data suggest that MSR-A ligands trigger signal pathways in THP-1 macrophages leading to the tyrosine phosphorylation of PLC-gamma 1 and PI 3-kinase.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 3.   Identification of tyrosine-phosphorylated PLC-gamma 1 (A) and PI 3-kinase (B). Cells were incubated with media alone (lane 1), LDL (lane 2), Ac-LDL (lane 3), or fucoidan (lane 4) as described in Fig. 2. Immunoprecipitation of the cell lysates was then performed with anti-PLC-gamma 1 monoclonal antibody (A) or anti-PI 3-kinase polyclonal antibody (B). The immunoprecipitates were resolved by SDS-PAGE, and immunoblots were probed with anti-phosphotyrosine monoclonal antibody as described under "Experimental Procedures." In addition, immunoprecipitates utilizing anti-PI 3-kinase polyclonal antibody from lysates of macrophage colony stimulating factor-treated cells were included as a positive control for phosphorylation of PI 3-kinase in B (lane 5).

Inhibitor of Tyrosine Kinase Reduces Ac-LDL- and Fucoidan-induced PKC Activity-- We have previously demonstrated that inhibitors of PKC were able to decrease the MSR-A ligand-induced uPA activity in RAW264.7 macrophages (2). Because Ac-LDL or fucoidan stimulates uPA expression and protein tyrosine phosphorylation in THP-1 macrophages (Figs. 1 and 2), we next determined whether the observed increase in protein tyrosine phosphorylation following incubation with MSR ligands can lead to an activation of PKC in THP-1 macrophages. As demonstrated in Fig. 4, incubation of THP-1 macrophages with Ac-LDL, fucoidan, or PMA (a positive control) quickly increased the PKC activity. In contrast, MSR-A ligands had no effect on PKA activity in THP-1 macrophages (data not shown). Moreover, the ability of MSR-A ligands to stimulate PKC activity was inhibited by herbimycin A (Fig. 4).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4.   Induction of PKC activity in human THP-1 macrophages by MSR-A ligation is inhibited by protein tyrosine kinase inhibitor. THP-1 macrophages were grown in 0.01% fetal calf serum, in the presence or absence of herbimycin A (5 µM) for 24 h at 37 °C. The cells were then treated with ligands of MSR: Ac-LDL (100 µg/ml) and fucoidan (20 µg/ml) or PMA (150 nM) for 5-120 min as indicated in the figure. At the indicated times, media were removed, and cells were washed and assayed for the PKC activity as described under "Experimental Procedures." PKC activity in untreated cells was assayed and assigned a relative value of 1. The data represent the mean ± S.E. of triplicate samples.

Inhibitors of Tyrosine Kinase and PKC Inhibit uPA Expression Induced by Ac-LDL and Fucoidan-- Because MSR-A ligands induce phosphotyrosyl proteins in THP-1 macrophages, including PLC-gamma 1 and PI 3-kinase, and the activation of PKC, we next determined the role of tyrosine kinase, PI 3-kinase, and PKC in MSR-A ligand-induced macrophage uPA secretion. For this purpose, we utilized the selective and potent inhibitors herbimycin A (40-43), wortmannin (44-46), and calphostin C (47-49) for tyrosine kinase, PI 3-kinase, and PKC, respectively. As seen in Fig. 5, THP-1 macrophage uPA expression was increased approximately 3-fold when incubated with fucoidan, whereas herbimycin A or calphostin C inhibited fucoidan-induced uPA activity without affecting constitutive expression. In contrast, preincubation of THP-1 macrophages with wortmannin did not affect fucoidan-induced uPA expression. These data demonstrate that the induction of uPA activity in THP-1 macrophage by MSR-A ligands is dependent on tyrosine kinases and PKC activation.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of inhibitors of protein tyrosine kinase, PI 3-kinase, and PKC on fucoidan-induced uPA expression by THP-1 macrophage. THP-1 macrophages (0.5 × 106/well) were preincubated with macrophage serum-free medium supplemented with herbimycin A (5 µM), wortmannin (25 nM), or calphostin C (50 nM) for 30 min. The MSR-A ligand fucoidan (20 µg/ml) was added, and cells were incubated overnight. Conditioned media were recovered and assayed for uPA activity as described under "Experimental Procedures."

Ac-LDL and Fucoidan Stimulate Protein Tyrosine Phosphorylation in MSR-transfected Human Bowes Melanoma Cells-- To support further our hypothesis that the MSR-A is a signaling receptor, we generated stable normal MSR transfectants from human Bowes melanoma cells. The expression of scavenger receptor in MSR transfectants was verified by flow cytometric analysis (Fig. 6). Moreover, we next determined whether expression of MSR-A by Bowes cells can lead to protein tyrosine phosphorylation following exposure to MSR-A ligands. As shown in Fig. 7, base-line levels of protein tyrosine phosphorylation were similar in normal MSR transfectants (N-MSR) and wild type cells. A 10-min exposure of cells to Ac-LDL resulted in increased levels of tyrosine phosphorylation in cells expressing MSR-A, whereas incubation of wild type cells with Ac-LDL did not appear to alter protein tyrosine phosphorylation. Following 60 min exposure to Ac-LDL, levels of tyrosine phosphorylation in wild type cells were increased but markedly less than that observed in MSR-A transfectants. Tyrosine phosphorylation induced by ligands for the MSR type A, fucoidan, was different than that observed with Ac-LDL in several ways. First, tyrosine phosphorylation in cells expressing MSR-A was dramatically increased following addition of fucoidan for 10 min. Second, fucoidan induced the phosphorylation of several low molecular weight proteins, which were not observed when cells were incubated with Ac-LDL. Third, wild type cells exposed to fucoidan exhibited a relatively small increase in protein tyrosine phosphorylation. Fourth, levels of tyrosine phosphorylation in MSR-A transfectants and wild type cells declined by 60 min. These data demonstrate that the ability of both Ac-LDL and fucoidan to induce protein tyrosine phosphorylation in Bowes cells is enhanced following transfection of MSR-A. However, these data do not exclude the possibility that Ac-LDL and fucoidan act via other receptors since both Ac-LDL and fucoidan stimulated relatively small changes in tyrosine phosphorylation in the wild type cells.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 6.   Flow cytometric demonstration of macrophage scavenger receptor expression on MSR-transfected Bowes cells. Wild type Bowes cells (dotted line) or normal MSR-transfected Bowes cells (solid line) were incubated in suspension with rabbit polyclonal anti-human macrophage scavenger receptor antibody for 30 min at 4 °C. Cells were then pelleted, resuspended in PBS/BSA containing fluorescein-conjugated goat F(ab')2 anti-rabbit immunoglobulins (gamma and light chains) for 30 min at 4 °C and analyzed by flow cytometry. Histograms demonstrate anti-human macrophage scavenger receptor antibody binding to the MSR-transfected Bowes cells but not the wild type Bowes cells. MSR-transfected Bowes cells incubated with control rabbit IgG alone did not show increased fluorescence (data not shown).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 7.   Stimulation of protein tyrosine phosphorylation in MSR-transfected Bowes cells upon ligand binding to MSR. Bowes, human melanoma cells stably transfected with the normal human macrophage scavenger receptor cDNA (N-MSR, lanes 1, 3, 5, and 7), and the parent wild type Bowes cells (Wt, lanes 2, 4, 6, and 8) were incubated with Ac-LDL and fucoidan as follows: both MSR-transfected Bowes cells and parent wild type Bowes cells were quiescent for 24 h in 0.01% fetal calf serum, and the cells were incubated with media alone (control), 100 µg/ml Ac-LDL, or 20 µg/ml fucoidan for the indicated periods at 37 °C. Cells were lysed in TL buffer and centrifuged. The supernatants were collected, and SDS sample buffer was added. The same amounts of protein were loaded to each lane. Immunoreactive phosphorylated tyrosine proteins were identified by Western blot procedures as described under "Experimental Procedures."

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The scavenger receptor type A plays an important role in several macrophage functions including adhesion (27, 28), clearance of pathologic substances (23, 25), and host defenses (4, 21). Although several studies have demonstrated alterations in macrophage function following incubation with MSR-A ligands (2-4), there is no evidence to date that the MSRs mediate these observed alterations in macrophage function. Previously, we and others (2, 50, 51) demonstrated that exposure of Corynebacterium parvum-activated peritoneal murine macrophages and murine macrophage cell lines (RAW264.7 and J774A.1 cells) to MSR-A ligands stimulates their secretion of uPA. In studies report here, we demonstrate for the first time that exposure of human THP-1 macrophages with MSR-A ligands can stimulate a series of signaling events, including activation of tyrosine kinase and PKC activities which lead to uPA expression. Moreover, exposure of Bowes melanoma cells transfected with MSR type A to either Ac-LDL or fucoidan can significantly up-regulate tyrosine kinase activity, whereas MSR-A ligands had no effect on mock-transfected cells. These data demonstrate that the binding of ligands to the MSR-A stimulates protein kinases leading to alterations in macrophage functions.

In these studies we have used human THP-1 macrophages to determine the role of MSR-A in uPA expression. THP-1 monocytes do not normally express MSR-A (30); however, when exposed to PMA, they differentiate into macrophage-like cells (30, 39, 52) and express MSR-A (30, 39, 53). Exposure of THP-1 monocytes that are devoid of scavenger receptor activity with MSR-A ligands did not affect steady state levels of uPA mRNA or their expression of uPA activity. In contrast, exposure of THP-1 macrophages with MSR-A ligands up-regulated uPA mRNA levels and uPA activity (Fig. 1 and Table I). Therefore, the MSR-A appears to play an important role in the regulation of THP-1 macrophage uPA expression.

To understand how binding of MSR-A ligands to the MSR-A is coupled to the initiation of signaling pathways leading to uPA expression in macrophage, several signaling cascades were initially examined. We found that Ac-LDL and fucoidan induced tyrosine phosphorylation of numerous proteins in THP-1 macrophages by Western blot analysis with monoclonal anti-phosphotyrosine IgG (Fig. 2A). Preincubation of cells with herbimycin A, an inhibitor of tyrosine kinase, blocked the ability of MSR-A ligands to induce tyrosine phosphorylation in THP-1 macrophages (Fig. 2B). In preliminary studies, we determined whether MSR ligands trigger tyrosine phosphorylation and increase uPA expression in fully differentiated human macrophages. Peripheral blood monocytes were allowed to differentiate in culture for 10 days. The monocyte-derived macrophages were then exposed to LDL, Ac-LDL, or fucoidan for 15 min, following which lysates were prepared. Based on Western blots, exposure of monocyte-derived macrophages to Ac-LDL or fucoidan resulted in an increase in protein tyrosine phosphorylation. When examined by Northern blot, the steady state level of uPA mRNA was elevated in cells following an overnight exposure to fucoidan.

Of the many phosphorylated proteins observed following incubation with MSR-A ligands, we identified PLC-gamma 1 and PI 3-kinase, two important signaling molecules, utilizing combined immunoprecipitation and Western blot analysis (Fig. 3, A and B). Tyrosine phosphorylation of PLC-gamma 1 and PI 3-kinase is also observed following engagement of growth factor receptors and cytokine receptors (54-57). However, MSR-A ligands do not function as growth factors and cytokines, and, unlike receptors for growth factor and cytokine, the MSR-A does not have an obvious functional tyrosine kinase domain (4, 37, 39). Therefore, these data suggest that signaling following engagement of the MSR-A is probably mediated by some associated cytosolic tyrosine kinase molecules.

It has been shown that PMA can stimulate macrophage uPA secretion (58, 59). Moreover, we demonstrated that the ability of the MSR-A ligand, fucoidan, to up-regulate murine RAW264.7 macrophage uPA expression can be blocked with inhibitors of PKC (2). In these studies preincubation of THP-1 macrophages with calphostin C, a specific PKC inhibitor, completely inhibited uPA secretion induced by the MSR-A ligands (Fig. 6). It is known that PKC can be activated by PLC-gamma 1-mediated cleavage of phosphatidylinositol 4,5-bisphosphate to generate 1,2-diacylglycerol (60, 61). Since PLC-gamma 1 is one of the proteins phosphorylated following exposure to MSR-A ligands, we determined whether exposure of cells to Ac-LDL or fucoidan up-regulated PKC activity. Incubation of THP-1 macrophages with MSR-A ligands leads to an increase in PKC activity (Fig. 4). These data suggest that activation of PLC-gamma 1 can stimulate PKC activity, which is followed by increased uPA expression. This conclusion is supported by data showing that phospholipase C increased uPA activity and mRNA levels in bone marrow-derived macrophage (62).

Furthermore, we found that herbimycin A inhibited Ac-LDL- and fucoidan-induced tyrosine phosphorylation of PLC-gamma 1 as well as their ability to increase PKC activity (Figs. 2B and 4). Herbimycin A can inhibit tyrosine phosphorylation of PLC-gamma 1 by an IgE-induced non-receptor tyrosine kinase (63). Moreover, inhibition of PLC-gamma 1 activation leads to decreased phospholipid hydrolysis and decreased PKC activity (63). These data suggest that engagement of the MSR-A leads to sequential activation of tyrosine kinase, PLC-gamma 1, and PKC.

Recently, the MSR-A has been identified as an opsonin-independent phagocytosis-promoting receptor. Moreover, MSR-dependent phagocytosis was involved in the activation of tyrosine kinase and PI 3-kinase (64). In these studies, we demonstrate that MSR-A ligands trigger signaling pathways leading to tyrosine phosphorylation of PI 3-kinase (Figs. 3 and 5). In fact, we found that preincubation of THP-1 macrophages with wortmannin, a potent and selective inhibitor of PI 3-kinase (44-46), had no effect on uPA expression induced by MSR-A ligands (Fig. 6), suggesting that PI 3-kinase may not involve MSR-mediated uPA activity. The role and significance of tyrosine phosphorylation of PI 3-kinase in MSR-mediated signaling in macrophages need further investigation.

Finally, to determine whether MSR-A plays a direct role in the observed signaling events including alterations in protein phosphorylation upon ligation, we stably transfected Bowes melanoma cells with the cDNA of normal MSR-A. MSR-transfected cells (N-MSR) challenged with lipoprotein (Ac-LDL) and non-lipoprotein (fucoidan) ligands of the receptor exhibited similar protein tyrosine phosphorylation patterns as THP-1 macrophages challenged with MSR-A ligands (Figs. 2A and 7). It is unclear why there is little nonspecific induction of protein tyrosine phosphorylation by both Ac-LDL and fucoidan in wild type Bowes cells (lanes 4 and 6 in Fig. 7). Interestingly, the protein tyrosine phosphorylation induced by fucoidan in MSR-transfected cells quickly returned to the basal level. In contrast, Ac-LDL-induced tyrosine phosphorylation increased over time. These results suggest that the kinetics for protein tyrosine phosphorylation induced by fucoidan and Ac-LDL is different. The physiological significance of this particular finding is unclear.

In summary, the activation of various signaling molecules including protein kinases in both macrophages and the MSR-transfected Bowes cells shows that the macrophage scavenger receptor type A can act as a signaling receptor. Additionally, because of its role in uPA activation, it may have a significant participant in tissue remodeling during inflammation and vascular diseases.

    FOOTNOTES

* These studies were supported by Research Grants R01 HL40819, K14 HL03158, T32 HL07423 and P01 HL46403 from the NHLBI of the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence may be addressed: Inst. of Biotechnology in Medicine/Faculty of Medical Technology, National Yang-Ming University, Taipei 112, Taiwan, ROC. E-mail: hyhsu{at}ym.edu.tu.

par To whom correspondence and reprint requests may be addressed: Dept. of Pathology (Rm. A678), 1300 York Ave., New York, NY 10021. Tel.: 212-746-6491; Fax: 212-746-8789; E-mail: dfalcone{at}mail.med.cornell.edu.

1 The abbreviations used are: MSR-A or MSR, macrophage scavenger receptor type-A; LDL, low density lipoprotein; Ac-LDL, acetylated-LDL; uPA, urokinase-type plasminogen activator; PLC-gamma 1, phospholipase C-gamma 1; PI 3-kinase, phosphatidylinositol-3-OH kinase; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; PAGE, polyacrylamide gel electrophoresis; BSA, bovine serum albumin; PBS, phosphate-buffered saline.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Falcone, D. J., and Ferenc, M. J. (1988) J. Cell. Physiol. 135, 387-396[Medline] [Order article via Infotrieve]
  2. Falcone, D. J., McCaffrey, T. A., and Vergilio, J. A. (1991) J. Biol. Chem. 266, 22726-22732[Abstract/Free Full Text]
  3. Palkama, T. (1991) Immunology 74, 432-438[Medline] [Order article via Infotrieve]
  4. Krieger, M., and Herz, J. (1994) Annu. Rev. Biochem. 63, 601-637[CrossRef][Medline] [Order article via Infotrieve]
  5. Ross, R. (1993) Nature 362, 801-809[CrossRef][Medline] [Order article via Infotrieve]
  6. Hansson, G. K., Seifert, P. S., Olsson, G., and Bondjers, G. (1991) Arterioscler. Thromb. 11, 745-750[Abstract]
  7. Jonasson, L., Holm, J., Skalli, O., Bondjers, G., and Hansson, G. K. (1986) Arterioscler. Thromb. 6, 131-138[Abstract]
  8. Gown, A. M., Tsukada, T., and Ross, R. (1986) Am. J. Pathol. 125, 191-207[Abstract]
  9. Munro, J. M., and Cotran, R. S. (1988) Lab. Invest. 58, 249-261[Medline] [Order article via Infotrieve]
  10. Goldstein, J. L., Ho, Y. K., Basu, S. K., Brown, M. S. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 333-337[Abstract]
  11. Pitas, R. E., Innerarity, T. L., and Weinstein, J. N. (1981) Arteriosclerosis 1, 177-185[Abstract]
  12. Shechter, I., Fogelman, A. M., Haberland, M. E., Seager, J., Hokom, M., Edwards, P. A. (1981) J. Lipid Res. 22, 63-71[Abstract]
  13. Haberland, M. E., Fogelman, A. M., and Edwards, P. A. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 1712-1716[Abstract]
  14. Parthasarathy, S., Fong, L. G., Otero, D., and Steinberg, D. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 537-540[Abstract]
  15. Sparrow, C. P., Parthasarathy, S., and Steinberg, D. (1989) J. Biol. Chem. 264, 2599-2604[Abstract/Free Full Text]
  16. Ottnad, E., Parthasarathy, S., Sambrano, G. R., Ramprasad, M. P., Quehenberger, O., Kondratenko, N., Green, S., Steinberg, D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1391-1395[Abstract]
  17. Nicholson, A. C., Pearce, S. F. A., Silverstein, R. L. (1995) Arterioscler. Thromb. Vasc. Biol. 15, 269-275[Abstract/Free Full Text]
  18. Naito, M., Suzuki, H., Mori, T., Matsumoto, A., Kodama, T., and Takahashi, K. (1992) Am. J. Pathol. 141, 591-599[Abstract]
  19. Brown, M., and Goldstein, J. (1983) Annu. Rev. Biochem. 52, 223-261[CrossRef][Medline] [Order article via Infotrieve]
  20. Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., Witztum, J. L. (1989) N. Engl. J. Med. 320, 915-924[Medline] [Order article via Infotrieve]
  21. Suzuki, H., Kurihara, Y., Takeya, M., Kamada, N., Kataoka, M., Jishage, K., Ueda, O., Sakaguchi, H., Higashi, T., Suzuki, T., Takashima, Y., Kawabe, Y., Cynshi, O., Wada, Y., Honda, M., Kurihara, H., Aburatani, H., Doi, T., Matsumoto, A., Azuma, S., Noda, T., Toyoda, Y., Itakura, H., Yazaki, Y., Horiuchi, S., Takahashi, K., Kruijt, J. K., van Berkel, T. J. C., Steinbrecher, U. P., Ishibashi, S., Maeda, N., Gordon, S., Kodama, T. (1997) Nature 386, 292-296[CrossRef][Medline] [Order article via Infotrieve]
  22. Pearson, A. M., Rich, A., and Krieger, M. (1993) J. Biol. Chem. 268, 3546-3554[Abstract/Free Full Text]
  23. Hampton, R. Y., Golenbock, D. T., Penman, M., Krieger, M., and Raetz, C. R. (1991) Nature 353, 342-344
  24. Nishikawa, K., Arai, H., and Inoue, K. (1990) J. Biol. Chem. 265, 5226-5231[Abstract/Free Full Text]
  25. Resnick, D., Freedman, N. J., Xu, S., and Krieger, M. (1993) J. Biol. Chem. 268, 3538-3545[Abstract/Free Full Text]
  26. Araki, N., Higashi, T., Mori, T., Shibayama, R., Kawabe, Y., Kodama, T., Takahashi, K., Shichiri, M., and Horiuchi, S. (1995) Eur. J. Biochem. 230, 408-415[Abstract]
  27. el Khoury, J., Thomas, C. A., Loike, J. D., Hickman, S. E., Cao, L., Silverstein, S. C. (1994) J. Biol. Chem. 269, 10197-10200[Abstract/Free Full Text]
  28. Fraser, L., Hughes, D., and Siamon, G. (1993) Nature 364, 343-346[CrossRef][Medline] [Order article via Infotrieve]
  29. Falcone, D. J., McCaffrey, T. A., Haimovitz-Friedman, A., and Garcia, M. (1993) J. Cell. Physiol. 155, 595-605[Medline] [Order article via Infotrieve]
  30. Hsu, H.-Y., Nicholson, A. C., and Hajjar, D. P. (1996) J. Biol. Chem. 271, 7767-7773[Abstract/Free Full Text]
  31. Hsu, H.-Y., Nicholson, A. C., and Hajjar, D. P. (1994) J. Biol. Chem. 269, 9213-9220[Abstract/Free Full Text]
  32. Hajjar, D. P., Falcone, D. J., Fabricant, C. G., Fabricant, J. (1985) J. Biol. Chem. 260, 6124-6128[Abstract/Free Full Text]
  33. Marshall, P., Warso, M., and Lands, W. (1985) Anal. Biochem. 145, 192-199[Medline] [Order article via Infotrieve]
  34. Chirgwin, J. M., Przybyla, A., and MacDonald, R. (1979) Biochemistry 18, 5894-5898
  35. Davis, L., Dibner, M., and Battery, J. (1986) Basic Methods in Molecular Biology, pp. 143-146, Elsevier Science Publishing Co., Inc., New York
  36. Roldan, A. L., Cubellis, V. M., Masucci, M. T., Behrendt, N., Lund, L. R., Dano, K., Appella, E., Blasi, F. (1990) EMBO J. 9, 467-474[Abstract]
  37. Matsumoto, A., Naito, M., Itakura, H., Ikemoto, S., Asaoka, H., Hayakawa, I., Kanamori, H., Aburatani, H., Takaku, F., Suzuki, H., Kobari, Y., Miyai, T., Takahashi, K., Cohen, E. H., Wydro, R., Housman, D. E., Kodama, T. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9133-9137[Abstract]
  38. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J. (1951) J. Biol. Chem. 193, 265-275[Free Full Text]
  39. Kodama, T., Freeman, M., Rohrer, L., Zabrecky, J., Matsudaira, P., and Krieger, M. (1990) Nature 343, 531-535[CrossRef][Medline] [Order article via Infotrieve]
  40. Uehara, Y., Hori, M., Takeuchi, T., and Umezawa, H. (1986) Mol. Cell. Biol. 6, 2198-2206[Medline] [Order article via Infotrieve]
  41. Uehara, Y., Fukazawa, H., Murakami, Y., and Mizuno, S. (1989) Biochem. Biophys. Res. Commun. 163, 803-809[Medline] [Order article via Infotrieve]
  42. Uehara, Y., and Fukazawa, K. (1991) Methods Enzymol. 201, 370-379[Medline] [Order article via Infotrieve]
  43. Lin, T. H., Yurochko, A., Kornberg, L., Morris, J., Walker, J. J., Haskill, S., Juliano, R. L. (1994) J. Cell Biol. 126, 1585-1593[Abstract]
  44. Okada, T., Sakuma, L., Fukui, Y., Hazeki, O., and Ui, M. (1994) J. Biol. Chem. 269, 3563-3567[Abstract/Free Full Text]
  45. Thelen, M., Wymann, M. P., and Langen, H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4960-4964[Abstract]
  46. Arcaro, A., and Wymann, M. P. (1993) Biochem. J. 296, 297-301[Medline] [Order article via Infotrieve]
  47. Jarvis, W. D., Turner, A. J., Povirk, L. F., Traylor, R. S., Grant, S. (1994) Cancer Res. 54, 1707-1714[Abstract]
  48. Gopalakrishna, R., Chen, Z. H., and Gundimeda, U. (1992) FEBS Lett. 314, 149-154[CrossRef][Medline] [Order article via Infotrieve]
  49. Kobayashi, E., Nakano, H., Morimoto, M., and Tamoaki, T. (1989) Biochim. Biophys. Res. Commun. 159, 548-553[Medline] [Order article via Infotrieve]
  50. Johnson, W. J., Pizzo, S. V., Imber, M. J., Adams, D. O. (1982) Science 218, 574-576[Medline] [Order article via Infotrieve]
  51. Falcone, D. J. (1989) J. Cell. Physiol. 140, 219-226[Medline] [Order article via Infotrieve]
  52. Tsuchiya, S., Kobayashi, Y., Goto, Y., Okumura, H., Nakae, S., Konno, T., and Tada, K. (1982) Cancer Res. 42, 1530-1536[Abstract]
  53. Via, D. P., Pons, L., Dennison, D. K., Fanslow, A. E., Bernini, F. (1989) J. Lipid Res. 30, 1515-1524[Abstract]
  54. Auger, K. R., Serunian, L. A., Soltoff, S. P., Libby, P., Cantley, L. C. (1989) Cell 57, 167-175[Medline] [Order article via Infotrieve]
  55. Ullrich, A., and Schlessinger, J. (1990) Cell 61, 203-212[Medline] [Order article via Infotrieve]
  56. Kapeller, R., and Cantley, L. C. (1994) BioEssays 16, 565-576[Medline] [Order article via Infotrieve]
  57. Camilli, P. D., Emr, S. D., McPherson, P. S., Novick, P. (1996) Science 271, 1533-1539[Abstract]
  58. Vassalli, J.-D., Hamilton, J. A., and Reich, E. (1977) Cell 11, 695-705[Medline] [Order article via Infotrieve]
  59. Vassalli, J.-D., Wohlwend, A., and Belin, D. (1992) Curr. Top. Microbiol. Immunol. 181, 65-86[Medline] [Order article via Infotrieve]
  60. Liscovitch, M., and Cantley, L. C. (1994) Cell 77, 329-334[Medline] [Order article via Infotrieve]
  61. Nishizuka, Y. (1995) FASEB J. 9, 484-496[Abstract/Free Full Text]
  62. Hamilton, J. A., Vairo, G., Knight, K. R., Cocks, B. G. (1991) Blood 77, 616-627[Abstract]
  63. Park, D. J., Min, H. K., and Rhee, S. G. (1991) J. Biol. Chem. 266, 24237-24240[Abstract/Free Full Text]
  64. Greenberg, S. (1995) Trends Cell Biol. 5, 93-99 [CrossRef]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.